Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Epidemiology, Biomarkers and Prevention

• Publication date

  2010-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1055-9965.EPI-10-0940PMID 21148757
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of cancer in a large cohort of U.S. veterans with diabetes

  2011cited by this paper
• Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16

  2010cited by this paper
• Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Effect of dutasteride on the risk of prostate cancer.

  2010cited by this paper
• Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer

  2010cited by this paper
• AMP‐activated protein kinase and cancer

  2009cited by this paper
• Insulin receptor expression by human prostate cancers

  2009cited by this paper
• Antidiabetic therapies affect risk of pancreatic cancer.

  2009cited by this paper
• Diabetes mellitus and risk of prostate cancer in the health professionals follow‐up study

  2009cited by this paper
• The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

  2009cited by this paper
• Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes

  2009cited by this paper
• Association of diabetes with prostate cancer risk in the multiethnic cohort.

  2009cited by this paper
• Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study

  2009influential reference
• Prostate cancer: a serious disease suitable for prevention

  2009influential reference
• New Users of Metformin Are at Low Risk of Incident Cancer

  2009cited by this paper
• Association of Diabetes and Body Mass Index with Levels of Prostate-Specific Antigen: Implications for Correction of Prostate-Specific Antigen Cutoff Values?

  2009cited by this paper
• National trends in treatment of type 2 diabetes mellitus, 1994-2007.

  2008cited by this paper
• Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.

  2008cited by this paper
• Insulin and insulin-like growth factor signalling in neoplasia

  2008cited by this paper
• Explaining the Race Difference in Prostate Cancer Stage at Diagnosis

  2008cited by this paper
• The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase

  2008cited by this paper
• Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.

  2008cited by this paper
• The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

  2008cited by this paper
• History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study

  2007cited by this paper
• Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

  2006cited by this paper
• Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin

  2006cited by this paper
• Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002.

  2006cited by this paper
• Predictors of glycemic control among patients with Type 2 diabetes: A longitudinal study

  2005cited by this paper
• Diabetes and risk of prostate cancer in a prospective cohort of US men.

  2005cited by this paper
• Metformin and reduced risk of cancer in diabetic patients

  2005cited by this paper
• The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin

  2005cited by this paper
• A randomised controlled trial to assess the effectiveness of offering study results as an incentive to increase response rates to postal questionnaires [ISRCTN26118436]

  2005cited by this paper
• History of diabetes mellitus and risk of prostate cancer in physicians.

  2004cited by this paper
• Human prostate cancer risk factors

  2004cited by this paper
• Diabetes mellitus and risk of prostate cancer (United States)

  2004cited by this paper
• Case-control study of lifetime total physical activity and prostate cancer risk.

  2004cited by this paper
• The influence of finasteride on the development of prostate cancer.

  2003cited by this paper
• The nested case-control study in cardiology.

  2003cited by this paper
• Evaluating medication effects outside of clinical trials: new-user designs.

  2003cited by this paper
• Validity of the General Practice Research Database

  2003cited by this paper
• Novel Approaches to Pharmacoepidemiology Study Design and Statistical Analysis

  2002cited by this paper
• Antihypertensive Therapy and Cancer Risk

  2001cited by this paper
• Validation of the diagnosis of venous thromboembolism in general practice database studies.

  2000cited by this paper
• Clinical information for research; the use of general practice databases.

  1999cited by this paper
• Use of the UK General Practice Research Database for pharmacoepidemiology.

  1998cited by this paper
• The UK General Practice Research Database.

  1997influential reference
• Lower Endogenous Androgen Levels and Dyslipidemia in Men with Non-Insulin-Dependent Diabetes Mellitus

  1992cited by this paper
• Validation of information recorded on general practitioner based computerised data resource in the United Kingdom.

  1991cited by this paper
• Endogenous sex hormone levels in older adult men with diabetes mellitus.

  1990cited by this paper
• Cancer statistics

  1989cited by this paper
• American Journal of Epidemiology Original Contribution Antidiabetic Medication and Prostate Cancer Risk: a Population-based Case-control Study

  year unknowninfluential reference
• American Journal of Epidemiology Original Contribution Diet, Supplement Use, and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

  year unknowncited by this paper

• Metformin treatment and reduction of gastrointestinal cancer risk: A 2-sample Mendelian randomization study

  2026cites this paper
• The Association Between Metformin Use and Prostate Cancer Incidence and Mortality: A Systematic Review and Meta-Analysis of Case-Control and Cohort Studies

  2025cites this paper
• Emerging uncertainty on the anti-aging potential of metformin.

  2025cites this paper
• Unravelling the association between metformin and pan-cancers: Mendelian randomization combined with NHANES database analysis

  2025cites this paper
• Understanding Cardiovascular Risk in Prostate Cancer: Role of Disparities, Diabetes, and Aging

  2024cites this paper
• Diabetes Mellitus and Prostate Cancer Risk—A Systematic Review and Meta-Analysis

  2024cites this paper
• Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies

  2024cites this paper
• Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes

  2023cites this paper
• Metformin and Dementia Risk: A Systematic Review with Respect to Time Related Biases

  2022cites this paper
• Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells

  2022cites this paper
• Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.

  2021cites this paper
• The Influence of Anti-Diabetic Drugs on Prostate Cancer

  2021cites this paper
• EliScholar – A Digital Platform for Scholarly Publishing at Yale

  2021influential citation
• Metformin use and the risk of anal intraepithelial neoplasia in type II diabetic patients

  2021cites this paper
• The Prevention and Control of Cancer by Metformin in Patients with Type 2 Diabetes: A Systematic Mapping Review

  2021cites this paper
• Association between metformin medication, genetic variation and prostate cancer risk

  2020cites this paper
• Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis.

  2020cites this paper
• Use of metformin and aspirin is associated with delayed cancer incidence.

  2020cites this paper
• Preventive and (Neo)Adjuvant Therapeutic Effects of Metformin on Cancer

  2020cites this paper
• History of coronary heart disease increased the mortality rate of patients with COVID-19: a nested case–control study

  2020cites this paper
• Steroid 5 alpha-reductase 2 enzyme variants, biomass exposure and tobacco use in Mexican patients with prostate cancer

  2020cites this paper
• Pharmacological interventions part IV: Metabolic modifiers

  2020cites this paper
• Impact of Putative Chemo-preventative Agents on Prostate Cancer Diagnosis among Men with a Negative First Prostate Biopsy

  2020cites this paper
• History of coronary heart disease increases the mortality rate of COVID-19 patients: a nested case-control study

  2020cites this paper
• Association between metformin medication, genetic variation and prostate cancer risk

  2020cites this paper
• Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.

  2019influential citation
• Metformin exposure and survival in head and neck cancer: A large population‐based cohort study

  2019cites this paper
• Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship

  2019cites this paper
• The Relationship between Prostate Cancer and Metformin Consumption: A Systematic Review and Meta-Analysis study.

  2019cites this paper
• The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis

  2019cites this paper
• Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.

  2019cites this paper
• Reduced risk of prostate cancer in a cohort of Lithuanian diabetes patients

  2019cites this paper
• Metformin for the chemoprophylaxis of cancer: an update systematic review about the role of metformin in cancer prevention.

  2019cites this paper
• Thérapeutique des désordres glycémiques

  2019cites this paper
• Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression

  2019cites this paper
• Role of Hedgehog Signaling in Breast Cancer: Pathogenesis and Therapeutics

  2019cites this paper
• Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study

  2019cites this paper
• Effects of diabetes mellitus and Metformin administration on prostate cancer detection at biopsy among Chinese men: a case-control study.

  2019cites this paper
• Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients

  2019cites this paper
• Metformin use and prostate cancer risk

  2019cites this paper
• Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study

  2019cites this paper
• Prostate Cancer Energetics and Biosynthesis.

  2019cites this paper
• The impact of metformin use on the risk of prostate cancer after prostate biopsy in patients with high grade intraepithelial neoplasia

  2018cites this paper
• Metformin and Colorectal Cancer - A Systematic Review.

  2018cites this paper
• Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis

  2018cites this paper
• Consequence of Energy Imbalance in Prostate Cancer and Comorbidities

  2018cites this paper
• Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: Effect on IGF‐1 and tumoral expression of IGF‐1 receptors☆

  2017cites this paper
• Aging, Metabolism, and Cancer Development: from Peto’s Paradox to the Warburg Effect

  2017cites this paper
• A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.

  2017cites this paper
• Metformin-induced anticancer activities: recent insights

  2017cites this paper
• Metformin to Treat Cancer: Misstep in Translational Research from Observational Studies.

  2017cites this paper
• CANCER AND DIABETES

  2017cites this paper
• A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer

  2017cites this paper
• Sirolimus and Metformin Synergistically Inhibits Colon Cancer In Vitro and In Vivo

  2017cites this paper
• Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis.

  2017cites this paper
• Metformin Does Not Predict for Prostate Cancer Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy

  2017cites this paper
• The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer

  2017cites this paper
• The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer

  2017cites this paper
• Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?

  2017cites this paper
• In-Vitro Antiproliferative Analysis of Metformin Hydrochloride on Androgen-Sensitive, LNCAP and Androgen-Insensitive, PC-3 Human Prostate Cancer Cell Lines

  2017cites this paper
• Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

  2017cites this paper
• Metformin and cancer: An existing drug for cancer prevention and therapy

  2017cites this paper
• Application of Marginal Structural Models with Inverse Probability of Treatment Weighting in Electronic Health Records to Investigate the Benefits and Risks of First Line Type II Diabetes Treatments.

  2017cites this paper
• Bioactivity and prostate tissue distribution of metformin in a preprostatectomy prostate cancer cohort

  2017cites this paper
• Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation

  2017cites this paper
• La metformine revisitée et consolidée en 2016 : un point de vue consensuel de l’Afrique à l’Europe

  2016cites this paper
• Regulation of prostate cancer cell function by activators of AMP-activated protein kinase

  2016cites this paper
• Metformin: A potential chemosensitizing agent for improving castration-resistant prostate cancer treatment

  2016cites this paper
• Does Metformin Reduce Cancer Risks? Methodologic Considerations

  2016cites this paper
• Prospective study of Type 2 diabetes mellitus, anti‐diabetic drugs and risk of prostate cancer

  2016cites this paper
• Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation

  2016cites this paper
• Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative

  2016cites this paper
• Potential role for metformin in urologic oncology

  2016cites this paper
• No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study

  2015cites this paper
• Metformin therapy and prostate cancer risk: a meta-analysis of observational studies.

  2015influential citation
• Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau)

  2015cites this paper
• Obesity and cancer: mechanistic insights from transdisciplinary studies.

  2015cites this paper
• Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study

  2015cites this paper
• METFORMIN AND SULFONYLUREAS EFFECT ON THE BLOOD LEVEL OF PROSTATE SPECIFIC ANTIGEN

  2015cites this paper
• Original Article Metformin therapy and prostate cancer risk: a meta-analysis of observational studies

  2015cites this paper
• Metformin and breast and gynecological cancer risk among women with diabetes

  2015cites this paper
• Metformin in cancer treatment and prevention.

  2015cites this paper
• Targeting the 5′-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer

  2015cites this paper
• Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer

  2015cites this paper
• Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator

  2015cites this paper
• Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta‐analysis

  2015cites this paper
• Chapitre 7 – Thérapeutique des désordres glycémiques

  2014cites this paper
• Effect of Metformin on Cancer Risk and Treatment Outcome of Prostate Cancer: A Meta-Analysis of Epidemiological Observational Studies

  2014cites this paper
• Diabetes therapy and cancer risk: Where do we stand when treating patients?

  2014cites this paper
• Comment on Bordeleau et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366

  2014cites this paper
• UvA-DARE ( Digital Academic Repository ) Fighting the Hydra : Optimizing treatment for type 2 diabetes

  2014cites this paper
• Future directions in the prevention of prostate cancer

  2014cites this paper
• The Effect of Diet, Exercise and Metformin on the Progression of Prostate Cancer

  2014cites this paper
• Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders

  2014cites this paper
• Reply from authors re: David Margel. Metformin to prevent prostate cancer: a call to unite. Eur urol 2014;66:1021-2.

  2014cites this paper
• Metformin to prevent prostate cancer: a call to unite.

  2014cites this paper
• Type 2 diabetes mellitus, glycemic control, and cancer risk

  2014cites this paper
• Metformin and Prostate Cancer among Diabetic Men

  2014influential citation
• Metformin use and prostate cancer risk.

  2014cites this paper
• Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor behind the Scene

  2014cites this paper